Roche’s Faricimab improves and maintains vision in two leading causes of vision loss: Lancet
All four studies met their primary endpoints, showing that people treated with Faricimab up to every four months achieved…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Category
Research
New therapeutic strategy targets old cells to prevent ageing
Scientists from Japan used this vaccine to eliminate senescent cells in mice and observed significant improvements in both the…
Innovent and Eli Lilly announce final clinical results and biomarker analysis of phase-Ib study of…
The Overall Response Rate (ORR) was 34 per cent (17/50) and ORRs for the low-dose and high-dose groups were 31 per cent and 38 per…
US FDA approves second indication for Skyrizi to treat adults with active psoriatic arthritis
Skyrizi maintains a dosing regimen for PsA that is consistent with the existing regimen for moderate-to-severe plaque psoriasis…
Chung-Ang University researchers show gold-paved path towards faster COVID-19 diagnosis
Researchers use gold nanoparticles to develop a new molecular diagnostic platform that considerably reduces the time required for…
Scientists demonstrate utility of bilateral tumour model for evaluating anti-cancer T-cell responses
A temporal analysis of T-Cell Receptors (TCRs) can be used to track changes in tumour-reactive T-cells of cancer patients…
Pfizer shares in-vitro efficacy of novel COVID-19 oral treatment against Omicron
The in-vitro studies suggest that Paxlovid has the potential to maintain plasma concentrations many-fold times higher than the…
US FDA grants priority review to Daiichi Sankyo and AstraZeneca’s sBLA of Enhertu
Enhertu is a HER2-directed Antibody Drug Conjugate (ADC) being jointly developed by Daiichi Sankyo and AstraZeneca for treatment…
IIT Mandi researchers discover phytochemicals in Himalayan plant that inhibit COVID-19 virus
Researchers show that phytochemical-rich petals of Rhododendron arboreum found in the Himalayan region, locally called “Buransh”…
Pfizer’s Prevnar 20 with Pfizer-BioNTech COVID-19 vaccine shows positive results in phase-III study
responses elicited by Prevnar 20 for all 20 serotypes were similar whether given with a dose of the Pfizer-BioNTech COVID-19…
New study shows novel strategy to improve quality checking of generic drugs
The strategy is likely to improve the regulatory and decision-making aspects related to pharmaceutical products
Novartis and Molecular Partners report positive topline data from phase-II study for Ensovibep
The secondary endpoint of hospitalisation and/or ER visits related to COVID-19, or death showed an overall 78 per cent reduction…
AbbVie submits applications for Upadacitinib in to US FDA and EMA
In the trial study, evaluating the efficacy and safety of Upadacitinib in adult patients with nr-axSpA, Upadacitinib met its…
Maharashtra health minister inaugurates BSV R&D centre at Airoli
The R&D centre will endeavour to bring scientifically-advanced biological, biotechnology products and novel drug delivery…
Leiden University Medica Center and Intravacc to start clinical trial with new intranasal corona…
Nasal spray vaccine based on soluble nano-spheres with synthetic corona proteins
Kintor Pharma announces first patient dosing of phase-III clinical trial of Pyrilutamide to treat…
On 24th November, 2021, Kintor Pharma announced that China's National Medical Products Administration (NMPA) greenlighted the…
Researchers at Technical University of Munich investigate mRNA nanoparticles
Researchers at the Heinz Maier-Leibnitz Zentrum (MLZ) used the high neutron flux available in Garching to characterise various…
Covaxin demonstrates robust safety and immunogenicity in two-to-18 year old: Study
Bharat Biotech had conducted phase-II/III, open-label and multi-centre studies to evaluate the safety, reactogenicity and…
Russian drug Avifavir effective against corona virus variants: ChemRar Group
The drug affects the highly conservative and mutation-resistant replication systems of RNA virus (RdRp) via three complementary…
China CanSinoBIO’s vaccine 57.5 per cent effective against COVID in phase-III trial: Study
The single-shot Ad5-nCoV vaccine, which CanSinoBIO co-developed with the Chinese military-backed Beijing Institute of…